The latest news on mergers and acquisitions featuring CSL, Vifor Pharma, Gilead Sciences, and MiroBio. Highlights below.

* CSL Gains Regulatory OK for $11.7-Bn Acquisition of Vifor Pharma
* Gilead Sciences To Acquire MiroBio for $405 M

---

CSL Gains Regulatory OK for $11.7-Bn Acquisition of Vifor Pharma
CSL, a Melbourne, Australia-based bio/pharmaceutical company, has received all necessary regulatory clearances for its $11.7-billion acquisition of Vifor Pharma, a St. Gallen, Switzerland-based specialty pharmaceutical company. CSL expects to close the acquisition by August 9, 2022. The companies had announced the acquisition in December 2021.  

Vifor is focused on products for iron deficiency, nephrology, and cardio-renal indications. It provides a complementary portfolio across CSL’s current therapeutic areas, including products for hematology and thrombosis, cardiovascular–metabolic, and transplant.

The acquisition will add 10 commercialized products to CSL’s portfolio, including Ferinject (ferric carboxymaltose)/Injectafer (ferric carboxymaltose injection), Venofer (iron sucrose), Veltassa (patiromer), and Korsuva (difelikefalin).

The combined company would have an expanded pipeline of 37 products across development phases, representing an increase of 37% from CSL’s current stand-alone pipeline, with up to four product launches expected in 2022/2023.

Source: CSL Limited

---

Gilead Sciences To Acquire MiroBio for $405 M
Gilead Sciences has agreed to acquire MiroBio, an Oxford, UK-based bio/pharmaceutical company, for approximately $405 million.

MiroBio is focused on developing therapeutics that restore immune balance with agonists targeting immune inhibitory receptors. The company has a proprietary drug-discovery platform, I-ReSToRE, to assess these receptors’ roles in immunity and their potential as therapeutic targets for immune-mediated disease. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and portfolio of immune inhibitory receptor agonists.

MiroBio’s lead investigational antibody, MB272, is in Phase I development and targets T, B, and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response.

Gilead says it anticipates advancing additional agonists derived from MiroBio’s I-ReSToRE platform, including a PD-1 agonist, MB151, and other undisclosed early-stage programs, over the next several years (as reported on August 4, 2022).

Source: MiroBio and Gilead Sciences